Invivoscribe offers a full range of oncology testing products and services (B- and T-cell clonality, NGS gene panels, MRD assays, and comprehensive bioinformatics software), all developed under ISO 13485 design control and manufactured in our cGMP facility.
I am pleased to take this opportunity to highlight a few of our company’s accomplishments from last year and identify a few of the many projects we will address in the coming year.
The pandemic that became apparent to us in the first quarter of 2020 understandably had a significant impact on our entire international staff and all of our customers worldwide last year. However, our executive and human resources team anticipated and prepared for teams working offsite, and our supervisors, LabPMM clinical, and Invivoscribe teams worldwide rapidly implemented and adjusted to new workflows, new schedules to address social distancing on site, and working with their families to adjust to keeping our business processes and momentum going while working from home. So, despite COVID-19-precipitated challenges, Invivoscribe remained focused and productive, completing, on time, projects for our partners, advancing internal projects, all combining to achieve high double-digit year over year revenue growth for the company.